RT Journal Article
SR Electronic
T1 Heart failure grading using single-lead electrocardiography
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.08.20209700
DO 10.1101/2020.10.08.20209700
A1 Hasumi, Eriko
A1 Fujiu, Katsuhito
A1 Chen, Ying
A1 Shimizu, Yu
A1 Oshima, Tsukasa
A1 Matsunaga, Hiroshi
A1 Matsuda, Jun
A1 Matsubara, Takumi J
A1 Fukuma, Nobuaki
A1 Yuxiang, Liu
A1 Sugita, Junichi
A1 Nakayama, Yukiteru
A1 Saga, Akiko
A1 Oguri, Gaku
A1 Kojima, Toshiya
A1 Maru, Yujin
A1 Shoda, Morio
A1 Komuro, Issei
YR 2020
UL http://medrxiv.org/content/early/2020/10/13/2020.10.08.20209700.abstract
AB Convolutional neural networks (CNNs) applied to electrocardiograms (ECGs) have been showing utility for detecting left ventricular (LV) dysfunction1. Although early detection of reduced LV ejection fraction (rEF) could improve handling of heart failure (HF) with rEF (HFrEF), it is not sufficient to detect HF with preserved EF (HFpEF). Here we developed a CNN algorithm to classify the severity of HF based on single-lead ECG data, irrespective of EF. We trained a CNN using ECG data and the HF classification from 7,865 patients with HF. The CNN achieved an area under the receiver-operating characteristic curve (AUC) of 0.996 for distinguishing patients with HF of various severity from healthy controls. It is anticipated that early detection of HF and therapeutic management of HF patients can be improved by employing this CNN with a single-lead ECG device.Competing Interest StatementA researcher belonged to both The University of Tokyo and SIMPLEX QUANTUM INC. The other employees of SIMPLEX QUANTUM INC. were not involved in any procedures of this study, including the design, collection, or analysis of the data.Clinical TrialThis study is retrospective study.Funding StatementThis study was partial financially supported by SIMPLEX QUANTUM INC., Tokyo, Japan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional ethical committee of the University of Tokyo (No. 2020024NI-(1)).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additional data is available.